Pharmaceutical ETFs in the biology trade
Large drugmakers. Driven by drug pricing rules and patent expiries.
6ETFs in this category
$6.1bnmoney in them
4.7%of the biology trade’s money
IHElargest unleveraged ETF, 26.4%
How they did, to Nov 2, 2026
| 1 month | YTD | 12 months | |
|---|---|---|---|
| Category median | +8.1% | +24.1% | +35.0% |
| Its story | +7.5% | +21.0% | +29.0% |
| Broad US ETFs | −2.5% | +11.5% | +11.8% |
Every ETF here, largest first
| # | ETF | Name | Assets | Share | 12 months | Fee |
|---|---|---|---|---|---|---|
| 1 | IHE | iShares U.S. Pharmaceuticals ETF | $1.6bn | 26.4% | +43.0% | 0.37% |
| 2 | FTXH | First Trust Nasdaq Pharmaceuticals ETF | $1.2bn | 19.3% | +46.7% | 0.60% |
| 3 | PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | $1.2bn | 19.3% | – | 0.13% |
| 4 | PPH | VanEck Pharmaceutical ETF | $1.1bn | 17.8% | +31.4% | 0.36% |
| 5 | PJP | Invesco Dynamic Pharmaceuticals ETF | $575m | 9.5% | +35.0% | 0.58% |
| 6 | XPH | SPDR S&P Pharmaceuticals ETF | $467m | 7.7% | +28.7% | 0.35% |
Other categories in the biology trade
Common questions
Which ETFs are pharmaceutical ETFs?6 US ETFs sit in this category of the biology trade. Large drugmakers. Driven by drug pricing rules and patent expiries.
What is the largest pharmaceutical ETF?IHE, iShares U.S. Pharmaceuticals ETF, with $1.6bn, 26.4% of the category's money.
How have pharmaceutical ETFs performed?The median unleveraged ETF here returned +35.0% over the last 12 months to Nov 2, 2026, against +11.8% for broad US ETFs. Past performance, not a forecast.